Adana City Education and Research Hospital, Department of Medical Oncology - Adana, Turkey.
Çukurova Üniversitesi, Faculty of Medicine, Department of Oncology - Adana, Turkey.
Rev Assoc Med Bras (1992). 2023 Feb 17;69(1):153-158. doi: 10.1590/1806-9282.20221123. eCollection 2023.
Breast cancer is the most common malignancy in women. In the treatment of these patients, pathological complete response is defined as the absence of invasive cancer in breast or lymph node tissue after the completion of neoadjuvant chemotherapy. In this study, we aimed to investigate the relationship of enhancer of zeste homolog 2 and mucin 1 expressions with pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy.
A total of 151 patients were included in the study. Enhancer of zeste homolog 2 and mucin 1 expressions were evaluated in the biopsy materials pre-neoadjuvant chemotherapy and post-neoadjuvant chemotherapy surgical material, and their relationship with pathological complete response was investigated.
The pathological complete response rates were significantly higher among the hormone receptor-negative patients, those with a high Ki-67 score, and patients with HER2-positive. Higher pathological complete response rates were obtained from patients with enhancer of zeste homolog 2 expression positivity pre-neoadjuvant chemotherapy. In addition, after neoadjuvant chemotherapy, enhancer of zeste homolog 2 expression was found to be completely negative in materials with pathological complete response; that is, in breast tissues considered to be tumor-free. While there was no significant relationship between mucin 1 expression and pathological complete response pre-neoadjuvant chemotherapy, mucin 1 expression was determined to significantly differ between the tissues with and without pathological complete response among the surgical materials examined.
In our study investigating the relationship between enhancer of zeste homolog 2 and mucin 1 expression and pathological complete response in patients who received neoadjuvant chemotherapy, we found that enhancer of zeste homolog 2 expression could be used as a predictive marker for pathological complete response. However, mucin 1 expression was not associated with pathological complete response.
乳腺癌是女性最常见的恶性肿瘤。在这些患者的治疗中，病理完全缓解定义为新辅助化疗完成后乳腺或淋巴结组织中无浸润性癌。在这项研究中，我们旨在研究接受新辅助化疗的乳腺癌患者中增强子结合蛋白 2 和黏蛋白 1 的表达与病理完全缓解的关系。
本研究共纳入 151 例患者。在新辅助化疗前和新辅助化疗后手术标本中评估增强子结合蛋白 2 和黏蛋白 1 的表达，并研究其与病理完全缓解的关系。
激素受体阴性、Ki-67 评分高和 HER2 阳性患者的病理完全缓解率显著更高。新辅助化疗前增强子结合蛋白 2 表达阳性的患者获得更高的病理完全缓解率。此外，新辅助化疗后，在被认为无肿瘤的乳腺组织中，增强子结合蛋白 2 表达完全为阴性，即病理完全缓解。虽然新辅助化疗前黏蛋白 1 表达与病理完全缓解之间无显著关系，但在检查的手术标本中，黏蛋白 1 表达在有和无病理完全缓解的组织之间存在显著差异。
在我们研究接受新辅助化疗的患者中增强子结合蛋白 2 和黏蛋白 1 表达与病理完全缓解之间的关系的研究中，我们发现增强子结合蛋白 2 表达可用作预测病理完全缓解的标志物。然而，黏蛋白 1 表达与病理完全缓解无关。
